Dosage and administration
Adults: One tablet daily as a dietary supplement, preferably with a meal, or as recommended by a healthcare professional.
Adults: One tablet daily as a dietary supplement, preferably with a meal, or as recommended by a healthcare professional.
Virelix Multivitamin
Dispensed by Prescription
85477-533-30
Reserved for Professional Recommendation
Virelix Tablets should be administered under the supervision of a licensed medical practitioner.
Virelix Tablets are orally administered prescription dietary supplement tablets intended to provide significant amounts of Vitamins B1, B3, B6, B12, C, D3, folic acid, and NADH to supplement the diet and help assure that nutritional deficiencies of these vitamins will not develop.
This listed product is not a National Drug Code,but instead has merely been formatted to comply with standard industry practice for pharmacy and insurance computer systems.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.
Manufactured for:
Oncora Pharma
Dallas TX 75228
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
Virelix Tablets should only be used under the direction and supervision of a licensed medical practitioner. Use with caution in patients that may have a medical condition, are pregnant, lactating, trying to conceive, under the age of 18, or taking medications.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Adults: One tablet daily as a dietary supplement, preferably with a meal, or as recommended by a healthcare professional.
CONTRAINDICATIONS
This product is contraindicated in patients with known hypersensitivity to any of the ingredients.
PRECAUTIONS
Use under the direction and supervision of a licensed healthcare professional.
ADVERSE REACTIONS
Allergic sensitization has been reported following oral administration of folic acid. Consult your physician immediately if adverse reactions occur.
KEEP OUT OF THE REACH OF CHILDREN.
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0854770533301 | GTIN-13: 0854770533301 EAN-13: 0854770533301 GTIN-12: 854770533301 UPC-A: 854770533301 GTIN storage (14 digits): 00854770533301 | virelix-1.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| cf050ccd-1144-f76a-e00d-e5698d8597d4 | Product name | 6 | 20250625 |
| 59361619-24d9-b610-eca6-5a7f25ed5e03 | Product name | 5 | 20240909 |
| b82b4008-22fd-05f5-6cc6-c0a6e81c65b8 | Product name | 2 | 20240805 |
| 91c62db0-0295-c81c-d10a-0856c259edd6 | Product name | 2 | 20200428 |
| d32bc2b8-0bb7-2216-87aa-24639646e202 | Product name | 3 | 20190619 |
| c5cd4727-ac49-4409-82b1-5bd8006c3ec7 | Product name | 1 | 20171122 |
| d206bb34-ea65-399d-70d9-834f22dc2c18 | Product name | 3 | 20170724 |
| 5e18e798-5614-cf5c-0185-38b1cb77a093 | Product name | 2 | 20160822 |
| 60c52429-fcef-eb54-2387-43bc9e4f296b | Product name | 1 | 20140508 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 85477-533 | 85477-533-30 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 3 | 2026-05-07 | full-release | 2026-06-01 02:52:54 |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ascorbic acid | ASCORBIC ACID | Zydus Pharmaceuticals USA Inc. | f0b683f8-189b-4a3f-9ffe-f91df6d798b6 | 2026-09-03 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascorbic acid | ASCORBIC ACID | Zydus Lifesciences Limited | d2d29ffd-5483-45bb-9d1b-da7af23b3720 | 2026-09-03 | ASCORBIC ACID | |
| Ascorbic Acid | ASCORBIC ACID | Renova Pharmaceuticals LLC | a6481bae-2397-44c7-a51d-4f47ad91bd2c | 2026-08-19 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascor | ASCORBIC ACID | McGuff Pharmaceuticals, Inc. | 388aad52-fc01-4784-9791-1dbc80c69306 | 2026-05-29 | Warnings, Adverse reactions | ASCORBIC ACID |
| Ascorbic Acid | ASCORBIC ACID | Fresenius Kabi USA, LLC | 1606e29f-0e80-4069-b688-daab9cbff20a | 2025-12-17 | Warnings, Adverse reactions | ASCORBIC ACID |
| Skin Renewing Serum | ASCORBIC ACID | Guangzhou Danting Bath&Body Care Industry Co. Ltd | 396c2a8d-ac95-cbef-e063-6294a90aff39 | 2025-08-23 | Warnings | ASCORBIC ACID |
Adverse event summaries are temporarily unavailable. Other product information remains available.